Nippon India Nifty Pharma ETF-Growth
Equity: Sectoral-Pharma - Growth (Open ended)
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: NIFTY Pharma Total Return IndexCheck Portfolio Overlap →
₹27.5+0.49%
18 Sept 2026
Similar ETFs
Side-by-side comparison of Nippon India Nifty Pharma ETF-Growth with similar ETFs — tracking error, returns, AUM and expense ratio.
| Period | This Fund | Category Avg | Category Rank |
|---|---|---|---|
| 1Y Return | +18.74% | 14.98% | 8 / 29 |
| 3Y Return | +20.35% | 20.76% | 7 / 18 |
| 5Y Return | +13.76% | 14.02% | 6 / 13 |
| 10Y Return | — | 13.64% | — |
Trailing annualised returns (%). Category rank: lower is better. Green = top third of category.
ETFs in Equity: Sectoral-Pharma
Top ETFs by AUM in the Equity: Sectoral-Pharma category — see how Nippon India Nifty Pharma ETF-Growth compares on size and returns.
Frequently Asked Questions
Which ETFs are similar to Nippon India Nifty Pharma ETF-Growth?
ETFs similar to Nippon India Nifty Pharma ETF-Growth in the Equity: Sectoral-Pharma category include ICICI Prudential Nifty Healthcare ETF-Growth, Groww BSE Hospitals ETF-Growth, and Aditya Birla Sun Life Nifty Healthcare ETF-Growth. These ETFs follow a comparable investment mandate and are benchmarked against similar indices. You can compare them in detail — across returns, risk metrics, expense ratio, and portfolio composition — using the ETF comparison tool on sharpely.
What is the rank of Nippon India Nifty Pharma ETF-Growth in its category?
On a 3-year return basis Nippon India Nifty Pharma ETF-Growth is ranked 7 out of 18 ETFs in the Equity: Sectoral-Pharma category as of 17 Sep 2026. On a 5-year return basis it ranks 6 out of 13. Consistently ranking in the top across multiple time periods is a stronger signal of ETF quality than a single-period rank.
How does Nippon India Nifty Pharma ETF-Growth's expense ratio compare to similar ETFs?
Nippon India Nifty Pharma ETF-Growth has an expense ratio of 0.23%. The peers ICICI Prudential Nifty Healthcare ETF-Growth has an expense ratio of 0.16% and Groww BSE Hospitals ETF-Growth has 0.54%. Over the long term, a higher expense ratio can meaningfully drag on returns, so it is worth evaluating whether the ETF's performance justifies the additional cost.
How does Nippon India Nifty Pharma ETF-Growth's AUM compare to similar ETFs?
Nippon India Nifty Pharma ETF-Growth has an AUM of ₹1,760.51 crore. The peers ICICI Prudential Nifty Healthcare ETF-Growth has an AUM of ₹236.93 crore and Groww BSE Hospitals ETF-Growth has ₹158.55 crore. A large AUM can sometimes limit a ETF's ability to take meaningful positions in mid and small-cap stocks, as larger trades can move prices. This is particularly relevant for ETFs that invest outside large caps.
Which ETF has the best 3-year returns in the Equity: Sectoral-Pharma?
The top performing ETF in the Equity: Sectoral-Pharma category on a 3-year basis is Motilal Oswal BSE Healthcare ETF-Growth with a CAGR of 22.06% as of 17 Sep 2026. Nippon India Nifty Pharma ETF-Growth has delivered 20.35% CAGR over the same period, ranking 7 out of 18 ETFs. You can view and compare the full category ranking on sharpely.
How does Nippon India Nifty Pharma ETF-Growth rank in risk-adjusted returns vs peers?
On a risk-adjusted basis, Nippon India Nifty Pharma ETF-Growth has a Sharpe ratio of 0.98 compared to the Equity: Sectoral-Pharma average of 0.97 as of 17 Sep 2026. It ranks 2 out of 5 ETFs in its category on Sharpe ratio.